From Name

From Email

To Name

To Email

Message

Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the United States

from American Journal of Clinical Pathology

Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the United States American Journal of Clinical Pathology Routine cervical screening of women 30 years and older using Papanicolaou (Pap) cytology and human papillomavirus (HPV) together (cotesting) was first approved by the U.S. Food and Drug Administration (FDA) in 2003. Since then, cotesting has steadily increased in the United States. FDA-approved cotesting is the preferred method for cervical screening of women 30 years and older in current American College of Obstetricians and Gynecologists guidelines and in joint guidelines from the American Cancer Society, American Society for Colposcopy and Cervical Pathology (ASCCP), and American Society for Clinical Pathology. READ MORE

more